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Background: Pulmonary arterial hypertension is a serious complication in scleroderma and
early diagnosis is warranted.
Patients and methods: 33 Scleroderma patients (mean age 54 [SD 11] years) with normal
systolic pulmonary artery pressure (sPAP), right and left ventricular parameters at rest were
enrolled in this study. They were investigated by echocardiography during physical exercise
and hypoxia. A hypertensive pulmonary vascular reaction was diagnosed when sPAP inappropri-
ately increased during exercise compared to individual exercise tolerance, or if sPAP was
>40 mm Hg during hypoxia exposure, respectively.
Results: In 17 patients there was a normal increase of sPAP at exercise of 34 [8] mm Hg (mean
VO2 max 70 [17]% predicted), and 29 [5] mm Hg during hypoxia. Sixteen patients developed
a hypertensive pulmonary vascular response with a sPAP of 47 [9] mm Hg during exercise (VO2-
max 64 [15]% pred.), and 54 [7] mm Hg mm Hg during hypoxia, respectively. The sPAP/VO2 max
ratio was higher in patients with a hypertensive response (0.76 [0.17] vs. 0.49 [0.12]
p< 0.0001). There was no difference in scleroderma subtype, duration of disease, gender or
age between groups. During a 3-year follow up one patient with a hypertensive response devel-
oped manifest pulmonary arterial hypertension.
Conclusion: Non-invasive assessment of pulmonary circulation during physical exercise and/or
hypoxia enables screening for pulmonary vascular dysfunction in scleroderma.
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Pulmonary arterial hypertension (PAH) is a serious compli-
cation in patients with scleroderma. In the CREST (calcinosis
cutis, Raynauds phenomenon, esophageal involvement,
sclerodactyly, teleangiectasia) variant of the disease about
15% of patients develop PAH.1 Recent studies have
confirmed the worse prognosis of scleroderma patients
with PAH, however current PAH treatment is able to
improve survival in these patients compared to historic
series.2,3
Current guidelines recommend annual screening with
standard echocardiography and measurement of systolic
pulmonary arterial pressure (sPAP) for early detection of
PAH in patients with scleroderma.4,5 This approach has not
yet resulted in an earlier diagnosis of pulmonary vascular
disease in these patients.1 Serial measurement of diffusion
capacity for carbon monoxide (DLCO) has been suggested
for prediction of PAH in scleroderma patients, however the
results differ between studies. A reduced DLCO is also
found in interstitial or emphysematous lung diseases.6e8
Therefore, newer and more sensitive methods for early
diagnosis of PAH are warranted.9
Early hemodynamic changes in pulmonary vascular
disease present with inappropriate increase in PAP during
exercise or stress.10e18 In scleroderma patients, noninva-
sive detection of increase in sPAP during exercise has been
associated with subsequent development of manifest
PAH.11
The increase of sPAP during exercise can be non-invasively
assessed by echocardiography. An increase in sPAP up to
40 mm Hg during exercise is regarded as normal pulmonary
vascular response to exercise. In contrast, a sPAP> 40 mmHg
during exercise is regarded as a hypertensive response
consistent with early pulmonary vascular dysfunction. This
method has been previously used to identify patients at risk
for development of PAH.11e14 However, the increase in sPAP
during exercise is associatedwith individual exercise capacity
and might exceed 40 mm Hg in good physical fitness, as
previously shown in healthy volunteers.19
An impaired pulmonary vascular function can also be
detected in response to hypoxia due to hypoxic pulmonary
vasoconstriction. An increase of sPAP> 40 mm Hg after 2 h
hypoxia exposure is regarded as a sign of pulmonary vascular
dysfunction.12,15,20
Against this background we aimed to test, if echocardi-
ography during cardiopulmonary exercise test and hypoxia
exposure could be used for non-invasive assessment of
pulmonary circulation in patients with scleroderma to
assess presence of early pulmonary vascular dysfunction.
Patients and methods
Between 1/2005 and 1/2007, we investigated all patients
with established scleroderma disease based on current
criteria,21 who were referred to our centre for screening for
PAH according to recent guideline.4
After history and physical examination, all patients
underwent pulmonary function test with DLCO, blood gas
analysis from arterialised earlobe sample and 12-lead elec-
trocardiogram (ECG) at rest. A peripheral venous bloodsample was taken for measurement of brain natriuretic
peptide (BNP) level (Shionoria BNP, CIS, Gif-sur-Yvette,
France).
Standard transthoracic echocardiography (SSD 4000,
Aloka, Vivid I, GEMedical, Munich, Germany) at rest included
measurements of left and right cardiac dimensions and
function. Doppler echocardiographic measurements
included assessment of left and right-sided valvular changes.
The sPAP was calculated using the trans-tricuspid pressure
gradient and adding estimated central venous pressure,
estimated by assessment of inferior vena cava diameters in
ex- and inspiration as described previously.22 When patients
had a normal left and right ventricular function without signs
suggestive of manifest PAH on echocardiography at rest,
patients underwent un-encouraged cardiopulmonary exer-
cise test (Vmax Sensormedics, Viasys Healthcare, Ho¨chberg,
Germany). Patients were asked to exercise up to their indi-
vidual limit on an exercise bicycle in a semi-supine position
tilted 30 degree towards the left side to obtain an optimal
echocardiographic window (Ergoline, Bitz, Germany). Exer-
cise protocol included increase in exercise load of 30 Wevery
2 min. Echocardiographic sPAP, heart rate, ECG and oxygen
saturation were recorded continuously and blood pressure
was measured every 2 min. Blood gas analyses from arter-
ialised earlobe samples were retrieved at rest and at
maximum exercise to calculate alveolar-arterial oxygen
difference (AaDO2).
When the performed tests did exclude any significant
cardiac disease, patients underwent hypoxia exposure.
Patients were asked to breathe an air mixture containing
an FiO2 of 12.5% through a facial mask in supine position
for 2 h, when the maximum pulmonary vascular response
to hypoxia can be expected.20 This oxygen concentration
is comparable to an altitude of 4500 m. Oxygen saturation
and heart rate were continuously recorded. Echocardio-
graphic examinations were performed every 30 min up to
2 h.
Echocardiographic examination was performed in a left-
sided position at rest and during hypoxia. Between the
exercise and hypoxia examinations patients had a resting
period of at least 1 h.
Echocardiographic examinations were performed by one
investigator (F.R.). Recordings were stored for off line
analysis performed by the study investigator and by 2
independent investigators (R.V., R.S.) who were unaware of
the study procedures.
Early pulmonary vascular dysfunction was diagnosed,
when sPAP increased above 40 mm Hg during cardio-
pulmonary exercise test or after 2 h hypoxia exposure,
respectively, consistent with a hypertensive pulmonary
vascular response. The increase in sPAP during exercise was
evaluated in respect to individual exercise capacity
measures by maximum oxygen uptake (VO2 max), which
can be also regarded as a surrogate parameter for cardiac
output.22 A ratio of sPAP max/VO2 % pred max> 0.6 has
been regarded as sign for early pulmonary vascular
dysfunction.16
Right heart catheter was performed by cannulation of
the internal jugular vein under local anaesthesia. Hemo-
dynamic parameters including the systolic and mean
pulmonary artery pressure, pulmonary artery wedge pres-
sures (PAWP), arterial and central venous oxygen saturation
PAH screening in scleroderma 1715were obtained at rest. Patients underwent a cardiopulmo-
nary exercise test using the same protocol with increase of
30 W every 2 min up to the individual limits. Hemodynamic
measurements with PAWP were obtained at every exercise
level as well as maximum exercise including arterial and
central venous saturation.
Afterwards, all patients remained in regular follow up
with annual screening echocardiography.
As data are normally distributed, they are presented as
mean [þ/standard deviation]. Significant differences
between groups were detected by using 2 tailed student t
test and Pearson Chi Square test as indicated. Correlations
were tested using Pearson’s correlation coefficient. A p
value <0.05 was regarded as statistically significant.
The study protocol had been approved by the Ethics
Committee of the University of Giessen, Germany and the
patients had given their informed written consent.Results
During the study period, 68 patients with scleroderma
had been referred for screening, evaluation and treatment
assessment to our pulmonary hypertension unit. Among
them, 35 patients had manifest pulmonary hypertension
according to recent guidelines,4 and were excluded from
the study. In the remaining 33 scleroderma patients, there
were no echocardiography signs of left or right ventricular
or valvular impairment at rest. None of these patients
presented with respiratory symptoms or dyspnoea. As
shown in Table 1, most of these patients were in the fifth
decade of their life and female gender clearly predomi-
nated (only two patients were males). Mean disease
duration was about 9 years and the majority of patients
suffered from limited forms of scleroderma (i.e. cutaneous
involvement, sicca and/or Raynaud symptoms). Only
3 patients had pulmonary fibrosis. On an average, pulmo-
nary function tests and blood gas analysis showed normal
results.Table 1 Baseline data of 33 scleroderma patients with hyperte
All patien
N 33
Age (years) 54 (11)
m/f 2/31
Scleroderma subtype limited/diffuse/overlap 27/5/1
Autoantibodies SCL 70/ACA/othera/no 8/18/3/4
Interstitial lung disease yes/no 3/30
Duration of disease (years) 9 (8)
BNP (mg/l) 147 (205)
FEV1 (% pred) 91 (15)
VC (% pred) 92 (15)
TLC (% pred) 105 (1)
DLCO (% pred) 85 (17)
pO2 (mm Hg) 85 (8)
sPAP (mm Hg rest) 23 (8)
ACA e anti-centromer-antibodies, BNP e brain natriuretic peptide, DL
forced expiratory volume in 1 second, m emale, pred e predicted, pO
pressure, TLC e total lung capacity, VC e vital capacity.
a Including anti fibrillarin antibiodies, and anti PM-Scl antibodies.Echocardiography during cardiopulmonary exercise test
and hypoxia challenge found a normal pulmonary vascular
reaction in 17 patients whereas a hypertensive pulmonary
vascular response was observed in 16 patients (see Table 2).
Patients with a hypertensive pulmonary vascular
response had a significantly higher sPAP at rest, during
exercise and hypoxia and a lower forced expiratory volume
in 1 s (FEV1), vital capacity (VC) and total lung capacity
(TLC) as % predicted compared to patients with normal
pulmonary vascular reaction. Between both groups, there
were no differences in maximum heart rate, Watt,
maximum oxygen uptake, ventilatory equivalents (EqO2,
EqCO2), and AaDO2 during exercise, and heart rate, oxygen
saturation and other echocardiographic parameters during
hypoxia and normoxia. Furthermore, there were no
differences in diffusion capacity, BNP level, and duration of
disease, age, or gender (Tables 1 and 2).
There was a good correlation between sPAP during
exercise and sPAP during hypoxia (rZ 0.67, p< 0.01), but
a better correlation was found between the index of sPAP/
VO2 max % pred and sPAP during hypoxia (rZ 0.72,
p< 0.01). There was no correlation between maximum VO2
% pred and sPAP during exercise (rZ 0.33) and sPAP during
hypoxia (rZ 0.1), respectively. The time course of sPAP
increase during hypoxia is shown in Fig. 1.
In 28 patients there was a similar increase in sPAP during
exercise and hypoxia, respectively (85%). The divergent
results in 5 patients were clarified using the sPAP/VO2 max
ratio, and 1 patient was classified as having a normal
response, and 4 patients having a hypertensive pulmonary
vascular response (Table 3). Three patients subsequently
underwent right heart catheterisation, where an exercise
induced pulmonary hypertension was confirmed (Table 4).
During the 3 years follow up, one patient of the hyper-
tensive group (patient 1 Table 4) developed an sPAP of
65 mm Hg with right ventricular dilatation at resting echo-
cardiography, and manifest PAH was confirmed by right
heart catheterisation (mPAP 30 mm Hg, CO 4.2 l/min,
pulmonary vascular resistance 380 dynes). The patient wasnsive or normal pulmonary vascular response in mean (SD).
ts Normal Hypertensive p
17 16
52 (11) 57 (11) 0.1
1/16 1/15
14/2/1 13/3/0 c2 0.3
4/9/1/3 4/9/2/1
1/16 2/14 c2 0.6
9 (9) 9 (7) 0.9
107 (102) 182 (262) 0.3
97 (14) 83 (14) 0.01
99 (13) 84 (14) 0.01
112 (14) 97 (15) 0.01
86 (14) 84 (20) 0.76
87 (5) 82 (10) 0.1
19 (4) 26 (9) 0.01
CO e diffusion capacity for carbon monoxide, f e female, FEV1 e
2 e partial pressure for oxygen, sPAP e systolic pulmonary arterial
Table 2 Exercise and hypoxia parameters of 33 patients with hypertensive or normal pulmonary vascular response in mean (SD).
All patients Normal Hypertensive p
Exercise
VO2 max (ml/kg/min) 15.4 (7.5) 17.5 (6.9) 13.1 (7.7) 0.1
VO2 max % pred 67 (17) 70 (17) 64 (15) 0.34
Max Watt 97 (33) 103 (33) 89 (37) 0.27
Max HR (min) 139 (20) 141 (23) 136 (17) 0.53
EqO2 35 (11) 32 (11) 38 (14) 0.18
EqCO2 38 (10) 37 (7) 39 (13) 0.66
AaDO2 max 21 (11) 19 (7) 23 (15) 0.4
sPAP max 40 (11) 34 (8) 47 (9) <0.0001
sPAP max/VO2 % pred 0.62 (0.2) 0.49 (0.12) 0.76 (0.17) <0.0001
Hypoxia
sPAP (mm Hg) 41 (14) 30 (6) 54 (7) <0.00001
SO2% 74 (10) 77 (11) 71 (9) 0.11
HR (min) 89 (14) 86 (16) 92 (12) 0.34
AaDO2 e arterioalveolar oxygen difference, EqCO2 e ventilatory equivalent for carbon dioxide, EqO2 e ventilatory equivalent for
oxygen, HR e heart rate, max e maximum, SO2 e oxygen saturation, sPAP e systolic pulmonary arterial pressure, VO2 e oxygen uptake.
1716 F. Reichenberger et al.subsequently started on pulmonary vasoactive treatment
with endothelin receptor antagonist.
Discussion
Pulmonary hypertension is a serious complication in
scleroderma affecting about 15% of patients. The high
prevalence of manifest PAH of 51% in our scleroderma
population is regarded as a referral bias to a specialised
unit for PAH at a tertiary university hospital. Risk stratifi-
cation for development of pulmonary vascular disease is of
great clinical impact. In 33 scleroderma patients without
signs of pulmonary hypertension at rest, we used a non-
invasive approach to detect early signs of pulmonary
vascular disease. We identified a subset of 16 patients (48%)
with a hypertensive pulmonary vascular response.
Previous studies described an exercise induced PAH
in 46e59% of patients with scleroderma and other0
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Figure 1 Increase in systolic pulmonary artery pressure
(sPAP) during hypoxia exposure comparing patients with
normal (open triangles) and hypertensive pulmonary vascular
reaction (closed triangles). The difference between both
groups can be detected throughout the hypoxia exposure and
was statistically significant after 120 min (p< 0.0001).autoimmune diseases, characterised by a sPAP> 40 mm Hg
at maximum exercise.11,13,18 However, increase in sPAP
during exercise is influenced by physical fitness19 and
therefore might be under- or overestimated. We used
a combined approach using increase of sPAP during
cardiopulmonary exercise test and hypoxia exposure.
Although hypoxia investigation is time consuming and
includes the exposure to somewhat ‘‘non-physiological’’
conditions, it has been used as exercise independent non-
invasive test for screening of pulmonary vascular
dysfunction.12,15,20,24
Indeed, 85% of patients had a similar result in both tests.
Although, 15% of patients showed divergent results, this
could be clarified by evaluation of sPAP during exercise in
respect to individual exercise tolerance. An sPAP/VO2 max
(% predicted) ratio >0.61 indicated a hypertensive pulmo-
nary vascular reaction, which was confirmed by right heart
catheter in 3 patients. In our opinion, this ratio improves
the value of exercise testing in detecting early pulmo-
nary vascular dysfunction without confirmation by means
of hypoxia exposure.
Between patients with normal and hypertensive pulmo-
nary vascular reaction, there was no difference in age,
gender, duration of disease or underlying organ complica-
tions, as all patients have also been assessed for signifi-
cant scleroderma associated interstitial lung disease.
Development of pulmonary vascular disease in sclero-
derma is not directly associated with these factors, as
recently confirmed in British and French surveys.1,25
Both patient groups showed a similar exercise capacity
as well as BNP levels and gas exchange parameters at rest
and during exercise. We regard the increase in sPAP during
exercise in our study too minor to influence exercise
tolerance. Patients with a hypertensive pulmonary vascular
reaction might be still in an asymptomatic state concerning
pulmonary vascular disease. Previous studies found
a reduced exercise capacity due to pulmonary vascular
disease in scleroderma patients with impaired gas exchange
at rest and increased BNP levels.11,26 An elevated BNP level
might indicate manifest PAH in scleroderma, but not stress
Table 3 Classification of pulmonary vascular response in 5 patients with divergent increase of sPAP during exercise and
hypoxia, respectively.
sPAP Baseline
(mm Hg)
sPAP hypoxia
(mm Hg)
sPAP exercise
(mm Hg)
VO2 max
(% pred)
sPAP/VO2
exercise
Classification
75y, f 26 36 50 97 0.52 Normal
46y, f 12 51 37 53 0.70 Hypertensive
77y, f 28 46 34 55 0.62 Hypertensive
66y, f 25 47 36 37 0.97 Hypertensive
70y, f 29 58 37 57 0.65 Hypertensive
f e female, max e maximum, pred. e predicted, sPAP e systolic pulmonary arterial pressure, VO2 e oxygen uptake.
PAH screening in scleroderma 1717induced PAH as shown in our study. However, its use is
compromised by high variability of the test results as shown
in our as well as in previous studies.
Right ventricular dysfunction has been recently
described to contribute to latent pulmonary hypertension
in scleroderma.27 This cannot be supported in our study, as
both groups of patients achieved a similar VO2 max, which
is regarded as a surrogate parameter for cardiac function.23
Patients with a hypertensive pulmonary vascular reaction
had significantly lower vital capacity and total lung capacity,
but within the normal limits. As diffusion capacity at rest,
and gas exchange during exercise were normal, the changes
in lung volumes are not related to underlying interstitial lung
disease. The difference in the lung volumes between both
groups may be attributed to a type I statistical error. Diffu-
sion capacity is known to be lower in manifest pH, but may
not indicate exercise induced pH.1,6,7 Only 3 patients with
interstitial pulmonary manifestation were included in the
study, and 2 of them had a hypertensive pulmonary vascular
reaction. The presence of some degree of interstitial
pulmonary disease also in the other patients cannot be
excluded, as we did not perform high resolution thoracic
computed tomography scan in the whole study population.
We regard the occurrence of a hypertensive pulmonary
vascular response as a risk for pulmonary vascular disease in
scleroderma patients to enable an individualised follow up.
With this non-invasive protocol we are able to obtainTable 4 Comparison of parameters at rest, during exercise,
undergoing right heart catheterisation. In patient 2, the differenc
level achieved during the right heart catheter study.
Patient 1, female,
43 yrs, CREST
RHC e CO rest 4.1 l/min
RHC e CO max 11.3 l/min
RHC e mPAP rest 17 mm Hg
RHC e mPAP max 45 mm Hg
RHC-PAWP rest 5 mm Hg
RHC e PAWP max 10 mm Hg
RHC e sPAP rest 24 mm Hg
RHC e sPAP max 60 mm Hg
ECHO e sPAP rest 22 mm Hg
ECHO e sPAP max 55 mm Hg
ECHO e sPAP hypoxia 44 mm Hg
sPAP e VO2-index 0.8consistent results, when increase in sPAP during exercise is
adjusted to individual exercise level. Indeed, one patient
with a hypertensive pulmonary vascular response devel-
oped manifest PAH in a 3-year follow up. In our opinion,
manifest pulmonary vascular disease might develop in
these patients but is not the inevitable consequence of
a hypertensive pulmonary vascular response.
The main limitation of our study is the rather low
number of patients investigated. Furthermore, we achieved
invasive confirmation of the results only in 9% of patients.
However, previous studies showed good correlation of
invasive and non-invasive measurement of sPAP during
exercise as well as hypoxia exposure.17,24 We consider our
approach as a non-invasive screening method. An invasive
confirmation of these results is required prior to any ther-
apeutic decision, as the non-invasive measurements are not
able to distinguish between pulmonary arterial and
pulmonary venous involvement. Furthermore, we cannot
exclude the possibly of beginning interstitial pulmonary
changes to contribute to pulmonary vascular dysfunction.
However, this hypothesis is not supported by the data with
normal gas exchange parameters during exercise.
In conclusion, non-invasive assessment of pulmonary
circulation during exercise enables detection of early
pulmonary vascular dysfunction in scleroderma patients.
Better results can be obtained when assessing sPAP
response in regard to individual exercise tolerance.during hypoxia, and invasive haemodynamics in 3 patients
e in RHC e sPAP and ECHO e sPAP is due to a higher exercise
Patient 2, female,
64 yrs, CREST
Patient 3, female,
55 yrs, CREST
4.6 l/min 3.4 l/min
10.2 l/min 9.6 l/min
18 mm Hg 13 mm Hg
40 mm Hg 31 mm Hg
9 mm Hg 5 mm Hg
13 mm Hg 8 mm Hg
20 mm Hg 19 mm Hg
63 mm Hg 46 mm Hg
25 mm Hg 20 mm Hg
36 mm Hg 45 mm Hg
47 mm Hg 45 mm Hg
0.97 0.67
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